Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca PLC Add to portfolio

LON100:AZN, Mar 28, 08:10 UTC

Latest LON100:AZN News

Filter your feed

Apply Filter

Yesterday


News

Asia-Pacific Respiratory Syncytial Virus (RSV) Market to 2028 - Featuring AstraZeneca, Bavarian Nordic & Enanta Pharmaceuticals Among Others - ResearchAndMarkets.com

AZN AZN

Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections. However, the global impact of new products in reducing the overall Respiratory Syncytial Virus (RSV) burden will depend on the cost-effectiveness of these drugs, as well as how vaccines are eventually integrated into national immunization policies throughout the 5GM - Australia, India, Japan, South Korea and urban China. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, March 26


News

AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia

AZN AZN

Zacks{{monthName}} {{day}}, {{year}}, {{hour12}}:{{minuteTwoDigit}} {{dayPeriod}}. AstraZeneca PLC AZN announced that the Japanese regulatory authority has granted marketing approval to Lokelma (sodium zirconium cyclosilicate) for the treatment of patients with hyperkalaemia in Japan. Lokelma is already marketed across the United States, Canada, Hong Kong, China, Russia and in the EU for the treatment of hyperkalaemia. Per the company, the nod by Japan’s Ministry of Health, Labour and Welfare (MHLW), was based on positive data from stand-alone studies in Japan as well as global evaluations. In a separate press release, AstraZeneca announced that it has collaboration with London-based biotech Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, March 25


News

BrightInsight Announces Global Digital Health Partnership with AstraZeneca

AZN AZN

SAN JOSE, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading regulated Internet of Things (IoT) platform for biopharma and medtech, announced today a global digital health partnership with global biopharmaceutical leader, AstraZeneca. AstraZeneca selected the regulated BrightInsight Platform for its growing portfolio of digital health products and services. “From our code to culture, BrightInsight is committed to supporting regulated digital health solutions across therapeutic areas, and we are honored to be selected by AstraZeneca to be its global digital health partner,” said Kal Patel, MD, CEO & Co-Founder, BrightInsight. “This partnership is an additional validation point that forward-thinking therapeutics companies like AstraZeneca see the value in leveraging the BrightInsight Platform, a scalable regulated IoT platform specifically designed for biopharma and medtech.”. AstraZeneca will develop apps, algorithms, Software as a Medical Device and connected devices on top of the BrightInsight Platform that enhance and personalize care while making overall healthcare delivery more efficient for patients and providers. “We quickly dismissed the concept of building our own custom platform so we could focus instead on developing transformational digital health solutions that bring to the forefront our deep-rooted history in science and focus on driving patient outcomes,” said Karan Arora, Chief Commercial Digital Officer and Global Vice President, AstraZeneca.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science
  • Technology

Monday, March 23


News

Health Care Sector Update for 03/23/2020: AYTU,HOTH,BLU,AZN,SINT

AZN

Health care stocks fell Monday with the NYSE Health Care Index declining 5.7% while the SPDR Health Care Select Sector ETF was down 4.8%. The Nasdaq Biotechnology index was dropping 0.7% this afternoon, reversing its prior advance. (+) Hoth Therapeutics (HOTH) climbed almost 39% after the company started a new joint venture with privately held Voltron Therapeutics to begin pre-clinical studies of a potential COVID-19 vaccine using Voltron's VaxCelerate platform licensed from the Vaccine and Immunotherapy Center at Massachusetts General Hospital in Boston. As part of the deal, Hoth is set to receive single digit royalties from product sales and the right to acquire up to 30% of the joint venture. (+) BELLUS Health (BLU) was ahead 19% after the company said it was re-acquiring its BLU-5937 and related P2X3 antagonists intellectual property assets from Canadian life sciences incubator adMare BioInnovations and AstraZeneca (AZN) in exchange for 4.7 million of its common shares.

Read Full Details

Story Sources

nasdaq.com nasdaq.com
Topics:
  • Business
  • Financial
  • Health

Friday, March 20


News

The Zacks Analyst Blog Highlights: Walmart, NVIDIA, AstraZeneca, Goldman Sachs and Global Payments

AZN NVDA +4 more AZN NVDA AZN GS GPN WMT

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart WMT, NVIDIA NVDA, AstraZeneca AZN, Goldman Sachs GS and Global Payments GPN. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. The Zacks analyst believes that NVIDIA is benefiting from strong growth in GeForce desktop and notebook GPUs, which is boosting gaming revenues.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, March 19


News

Top Stock Reports for Walmart, NVIDIA & AstraZeneca

AZN NVDA +2 more AZN NVDA AZN WMT

Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), NVIDIA (NVDA) and AstraZeneca (AZN). The Zacks analyst believes that the company’s e-commerce sales surged on robust online grocery performance. Management expects e-commerce sales to rise nearly 30% in fiscal 2021, wherein International sales are likely to grow 4%. However, Walmart’s earnings broke its positive surprise trend and fell year over year in the quarter due to higher cost of sales and increased operating, selling, general and administrative expenses. (You can read the full research report on NVIDIA here >>>). AstraZeneca’s shares have lost -22.4% over the past three months against the Zacks Large Cap Pharmaceuticals industry’s fall of -15.8%.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, March 17


News

AstraZeneca's Imfinzi shows sustained benefit in lung cancer study

AZN AZN

Visit our Privacy Policy to learn more or manage your personal preferences in our Cookie Consent Tool. AstraZeneca's Imfinzi shows sustained benefit in lung cancer study. (Reuters) - AstraZeneca Plc said on Tuesday longer-term data from a late-stage trial on its cancer drug, Imfinzi, in combination with chemotherapies showed sustained improvement in overall survival of certain lung cancer patients, sending its shares up 4%. The results confirm a previous set of data from the same study, which was published in September and had led the U.S. Food and Drug Administration to give the drug a priority review status two months later. AstraZeneca has been trying to broaden the use of Imfinzi, which was the first immunotherapy to be approved for stage III lung cancer, by testing it as a standalone and a combo treatment for different forms of cancer. The study also tested the combination of Imfinzi with another immunotherapy, tremelimumab, as a first-line treatment in patients with extensive-stage small cell lung cancer, the company said. However, the treatment failed to meet the main goal of improving overall survival in patients, its second such setback in less than a month.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

AstraZeneca's lung cancer treatment fails to meet main goal

AZN AZN +1 more AZN AZN TRI

March 17 (Reuters) - AstraZeneca Plc AZN.L said on Tuesday its combo treatment for a form of lung cancer failed to meet the main goal of improving overall survival in patients in a late stage study, its second such setback in less than a month. The drugs belong to an immunotherapy class of treatments, which strengthen the body's defenses to fight cancer and tumors. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D'Silva). ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;)).

Read Full Details

Story Sources

nasdaq.com nasdaq.com
Topics:
  • Business
  • Health
  • Financial
  • Entertainment
  • Technology

Monday, March 16


News

Global PEGylated Protein Therapeutics Market Study 2020-2026 Amgen Inc., AstraZeneca PLC, Biogen Inc. – Bandera County Courier

AZN AZN +1 more AZN AZN AMGN

PEGylated Protein Therapeutics Market report It helps them get a sense of what is happening in an industry, i.e., demand-supply statistics, PEGylated Protein Therapeutics Market degree of competition within the industry, PEGylated Protein Therapeutics Market competition of the business with different rising industries, future prospects of the business. It is considered as extraordinary findings that accountable to offer insightful details into some essential attributes related to the global PEGylated Protein Therapeutics Market 2020. The Global PEGylated Protein Therapeutics market worth about xx billion USD in 2020 and it is expected to reach xx billion USD in 2026 with an average growth rate of x%. United States is the largest production of PEGylated Protein Therapeutics Market and consumption region in the world, Europe also play important roles in global PEGylated Protein Therapeutics market while China is fastest growing region.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, March 13


News

AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails

AZN AZN +1 more AZN AZN MRK

Zacks{{monthName}} {{day}}, {{year}}, {{hour12}}:{{minuteTwoDigit}} {{dayPeriod}}. AstraZeneca plc AZN and partner Merck MRK announced that a phase III study evaluating a combination regimen of their successful PARP inhibitor, Lynparza in patients with platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint. The GY004 study was led by NRG Oncology and sponsored by the U.S. National Cancer Institute (NCI) and evaluated the safety and efficacy of a potential new medicine cediranib added to Lynparza versus platinum-based chemotherapy in the above patient population. Shares of AstraZeneca and Merck declined 8.6% and 6.1%, respectively on Thursday in response to the news and also due to coronavirus related market sell-off. Lynparza is also under priority review in the United States for metastatic castration-resistant prostate cancer (with HRR genetic mutations) and for first-line advanced ovarian cancer (maintenance therapy) in combination with Roche’s RHHBY Avastin regardless of patients’ biomarker status or surgical outcome.

Read Full Details

Topics:
  • Business
  • Health
  • Financial